EDAP TMS S.A. Announces Exclusive Distribution Of New Muscle Trainer Device In Japan

EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide portfolio of minimally invasive medical devices primarily for the treatment of urological diseases is proud to report it recently signed a new agreement with the Japanese importer Medi Trend K.K. for exclusive distribution of the "PB Trainer" device in Japan. This new muscle trainer device delivers similar effects to Kegel exercises for the pelvic floor. PB Trainer was fully developed and manufactured by Neotonus Inc. (USA) and uses the revolutionary Extracorporeal Magnetic Innervation technology (ExMIT) to stimulate and to help users to exercise all of the muscles of the pelvic floor region. In addition to being painless and non- invasive, the PB Trainer requires no active participation by the user.

Julien Laronze, CEO of the Japanese offices, commented, "This will unmistakably mark a milestone for our expansion in Japan. I clearly believe the Japanese team is on the right path to achieve the commercial objectives that will continue reinforcing the group focus on the long-term opportunities in this country and in Asia for products from both EDAP and complementary companies."

Takamasa Sugiura, CFO of the Japanese offices since 2002 and responsible for the company's finance and administration as well as local SEC compliance and reporting, added, "The portfolio of medical devices distributed today by our offices in Japan has excellent potential. The integrity and dedication of the management team along with the support of the highly qualified Japanese staff will surely provide the right grounds for us to progress in the upcoming years. I sincerely look forward to seeing our structure in Japan expand steadily in the upcoming years."

Marc Oczachowski, COO of EDAP TMS commented, "This distribution agreement reinforces EDAP's leading position in Asia and Japan as provider of minimally invasive urology devices. We own a strong and highly regarded worldwide distribution and service network with the depth necessary to succeed with internal products and those of companies seeking access to these key urology markets. Expanding on marketing and adding new high technology products to our portfolio is fully in line with EDAP's strategy to leverage our current distribution network capacity."

The company will be attending the upcoming 95th Annual Meeting of Japanese Urological Association (JUA) Congress scheduled in Kobe city this year April 14-17. Company products and clinical results will be presented during this convention. According to the information gathered by the authorities in charge of the JUA Congress this year, more than 6,000 participants are expected to join the exclusive event.

The Japanese headquarters of the company are based in Tokyo, with branch offices in Osaka, Sapporo, Fukuoka, and Okayama.

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm- HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

EDAP TMS S.A.
http://www.edap-tms.com